Using a variety of mouse tumor models, Gao et al. showed that tumor-infiltrating NKs (CD49a−CD49b+) could be converted to an intermediate ILC1 (intILC1, CD49a+CD49b+) phenotype characterized by reduced Eomes and increased CD49a expression. The gene discussed is ITGA2; the disease is neoplasm.